trial

An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia

NCTId NCT01309373

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase — · Completed

Enrollment 1,809 (actual)

Sponsored by Janssen-Cilag Farmaceutica Ltda.

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Completed

Enrollment

1,809 (actual)

Study type

Observational

Allocation

—

Model

—

Masking

—

Start

2010-11

Primary completion

—

Eligibility

ALL · 18 Years · 65 Years

Interventions & indications

Drugs

Patient assessment

Indications

Schizophrenia Schizoaffective Disorder Schizophrenia Psychotic Disorders

Sites

0 total

Facts & assertions

3 sourced

Enrollment

1,809

Phase

Status

COMPLETED

relationships

The graph out of here

drug

Patient assessment

drug

lead_sponsor

Janssen-Cilag Farmaceutica Ltda.

company

indication

Schizophrenia

indication

Schizoaffective Disorder

indication

Schizophrenia

indication